PTGX
Protagonist Therapeutics Inc.
Latest News for PTGX
Citi analyst Geoff Meacham maintained a Buy rating on Protagonist Therapeutics on May 7 and set a price target of $130.00. The company’s shares clo......
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Protagonist Therapeutics today and set a price target of $117.00. Tsao covers the H......
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on TScan Therapeutics (TCRX), Protagonist Therapeutics ......
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Protagonist Therapeutics today and set a price target of $117.00. Tsao covers the H......
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on TScan Therapeutics (TCRX), Protagonist Therapeutics ......
In a report released today, Etzer Darout from Barclays maintained a Buy rating on Protagonist Therapeutics, with a price target of $119.00. Accordi......
News data is sourced from MarketXLS API and updated regularly.
Showing 6 of 6 articles.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PTGX | $99.98 | +0.8% | 360.75K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Protagonist Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW